Double scan strategy could sharpen prostate cancer staging

NCT ID NCT07455097

Ongoing Diagnosis Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether combining PSMA-PET/CT and MRI scans can more accurately determine the extent of prostate cancer in men with intermediate- or high-risk disease. Researchers will compare scan results with tissue samples from 600 men who had their prostate removed. The goal is to improve staging and guide personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSMA-11 (diagnostic tracer)
What this could lead to: If successful, this could lead to more accurate staging of prostate cancer, helping doctors choose better treatments and avoid unnecessary surgery.
What could go wrong: This is a retrospective analysis, not a controlled trial, so results may not apply to all patients. The imaging techniques are already in use, so the benefit may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK PROSTATE CANCER INTERMEDIATE RISK PROSTATE CANCER

Contacts and locations

Locations

Fortis Hospital

Kolkata, India
KU Leuven

Leuven, Belgium
Ludwig-Maximilians-University Munich

Munich, Germany
Lund University Hospital

Lund, Sweden
Marienhospital Herne

Herne, Germany
Medical University Vienna

Vienna, Austria
San Raffaele University Hospital Milan

Milan, Italy
University Hospital Bern

Bern, Switzerland
University Hospital Düsseldorf

Düsseldorf, 40225, Germany
University Hospital Tübingen

Tübingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.